Outcome of treatment for castration-resistant prostate cancer with homologous recombination repair-related gene mutations (multiinstitutional prospective observational study). - HRRCAP

Goto Takayuki0 个研究点目标入组 400 人开始时间: 2023年5月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with castration-resistant prostate cancer who have mutations in any of the following homologous recombination repair-related genes as a result of germline analysis (BRACAnalysis) or cancer panel testing with all of the following HRR-related 15 genes as targets, and who have agreed to a prospective observational study
•Homologous recombination repair gene mutations of interest: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L
•2) Patients who have agreed to undergo genetic analysis of their blood before starting treatment and at the time of acquisition of resistance to treatment when using PARP inhibitors or platinum drugs or immune checkpoint inhibitors during prospective observational studies
•3) Those who were 20 years of age or older at the time of obtaining consent

•1) Patients for whom routine follow-up, including imaging, is not possible due to comorbidities or other reasons
•2) Other patients deemed unsuitable by the principal investigator or sub-investigator to conduct the study

发起方

Goto Takayuki